Pharmacological enhancement of motor function recovery in patients with ischaemic stroke: a trial of fluoxetine.

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR201412000967245

Enrollment

Registered

2014-12-10

Start date

2015-01-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Interventions

fluoxetine plus standard treatment

standard treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) 18- 85yrs of age (2) Ischaemic stroke, unilateral, supra-tentorialconfirmed by neuroimaging. (3) Presentation within first 14 days of ictus (4) NIHSS score </= 16 (5) Hemiparesis or hemiplegia, FMMS </=55 (6) Informed consent.

Exclusion criteria

Exclusion criteria: (1) Glasgow coma score 16 (3) Cardiovascular/metabolic /respiratory instability-: hypertensive emergency or hypotension/ acidosis or alkalosis/ RR >24cycles per min. (4) Previous central /peripheral nerve injury (5) Concurrent medications interacting with SSRI¿s (6) Haemorrhagic stroke on CT (7) Substantial premorbid disability (8) Depression (Montgomery-Åsberg Depression Rating Scale MADRS score >19), taking anti-depressant drugs, MAOI, neuroleptic drugs or benzodiazepines during the month before inclusion. (9) Pregnancy. (10) No consent.

Design outcomes

Primary

Measure	Time frame
Changes in Fugl Meyr Motor score	—

Secondary

Measure	Time frame
NIHSS, mRS	—

Countries

Nigeria

Contacts

Public ContactDike franklin

senior registrar

frankincense4m@yahoo.com+2347033038651

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026